Reuters logo
BRIEF-Ardelyx's Phase 3 study of Tenapanor for IBS-C hits primary and secondary endpoints
October 11, 2017 / 9:00 PM / 2 months ago

BRIEF-Ardelyx's Phase 3 study of Tenapanor for IBS-C hits primary and secondary endpoints

Oct 11 (Reuters) - Ardelyx Inc

* Ardelyx’s pivotal Phase 3 study of Tenapanor for IBS-C hits primary and all secondary endpoints to support NDA submission in 2018

* ‍Study hit statistical significance for primary endpoint and all secondary endpoints evaluated for topline results​

* Ardelyx Inc - ‍six of 12-week combined responder rate shows clear benefit in treated patients with consistent response throughout 26 weeks in trial​

* Ardelyx Inc - ‍Tenapanor was well-tolerated in treated patients​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below